Format

Send to

Choose Destination
Pharm Res. 2014 Jul;31(7):1823-33. doi: 10.1007/s11095-013-1286-y. Epub 2014 Jan 24.

One mouse, one pharmacokinetic profile: quantitative whole blood serial sampling for biotherapeutics.

Author information

1
Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer, Inc., One Burtt Road, Andover, Massachusetts, 01810, USA.

Abstract

PURPOSE:

The purpose of this study was to validate the approach of serial sampling from one mouse through ligand binding assay (LBA) quantification of dosed biotherapeutic in diluted whole blood to derive a pharmacokinetic (PK) profile.

METHODS:

This investigation compared PK parameters obtained using serial and composite sampling methods following administration of human IgG monoclonal antibody. The serial sampling technique was established by collecting 10 μL of blood via tail vein at each time point following drug administration. Blood was immediately diluted into buffer followed by analyte quantitation using Gyrolab to derive plasma concentrations. Additional studies were conducted to understand matrix and sampling site effects on drug concentrations.

RESULTS:

The drug concentration profiles, irrespective of biological matrix, and PK parameters using both sampling methods were not significantly different. There were no sampling site effects on drug concentration measurements except that concentrations were slightly lower in sodium citrated plasma than other matrices.

CONCLUSIONS:

We recommend the application of mouse serial sampling, particularly with limiting drug supply or specialized animal models. Overall the efficiencies gained by serial sampling were 40-80% savings in study cost, animal usage, study length and drug conservation while inter-subject variability across PK parameters was less than 30%.

PMID:
24464271
DOI:
10.1007/s11095-013-1286-y
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center